| First Author | Novy MJ | Year | 2022 |
| Journal | Neurobiol Aging | Volume | 110 |
| Pages | 73-76 | PubMed ID | 34875506 |
| Mgi Jnum | J:319797 | Mgi Id | MGI:6865575 |
| Doi | 10.1016/j.neurobiolaging.2021.10.015 | Citation | Novy MJ, et al. (2022) Expression and proteolytic processing of the amyloid precursor protein is unaffected by the expression of the three human apolipoprotein E alleles in the brains of mice. Neurobiol Aging 110:73-76 |
| abstractText | The 3 human apolipoprotein E (APOE) gene alleles modify an individual's risk of developing Alzheimer's disease (AD): compared to the risk-neutral APOE epsilon3 allele, the epsilon4 allele (APOE4) is strongly associated with increased AD risk while the epsilon2 allele is protective. Multiple mechanisms have been shown to link APOE4 expression and AD risk, including the possibility that APOE4 increases the expression of the amyloid precursor protein (APP) (Y-W.A. Huang, B. Zhou, A.M. Nabet, M. Wernig, T.C. Sudhof, 2019). In this study, we investigated the impact of APOE genotype on the expression, and proteolytic processing of endogenously expressed APP in the brains of mice humanized for the 3 APOE alleles. In contrast to prior studies using neuronal cultures, we found in the brain that both App gene expression, and the levels of APP holoprotein were not affected by APOE genotype. Additionally, our analysis of APP fragments showed that APOE genotype does not impact APP processing in the brain: the levels of both alpha- and beta-cleaved soluble APP fragments (sAPPs) were similar across genotypes, as were the levels of the membrane-associated alpha- and beta-cleaved C-terminal fragments (CTFs) of APP. Lastly, APOE genotype did not impact the level of soluble amyloid beta (Abeta). These findings argue that the APOE-allele-dependent AD risk is independent of the brain expression and processing of APP. |
